From Egypt to Europe, Raghda Moussa is using artificial intelligence to support safer, more precise, and more personalized medical decisions. But where does the algorithm end, and where does clinical responsibility begin?
Medication errors are among the leading causes of preventable complications in healthcare. Each year, they harm millions of patients worldwide, with global costs estimated at $42 billion, according to the World Health Organization. Beyond the economic impact, the human cost is substantial. In Egypt, Raghda Moussa is working within this landscape. With HealNOSTiC, she has developed a deep-tech platform that uses AI to prevent medication errors, generate intelligent drug insights, and advance precision medicine. The company’s motto is explicit: “Trusted Intelligence for Safer, Smarter Medication Decisions.” The goal is to support medical decisions that are better informed, safer, and more tailored to individual patients, wherever they are.
TAKEAWAYS
An ecosystem for all healthcare stakeholders
Within the crowded health-tech landscape, HealNOSTiC positions itself as an integrated, multi-target solution. The platform includes deep-tech mobile applications for real-time decision support, personalized wellness features linked to pharmacological therapy, and next-generation B2B platforms for clinicians, payers, and healthcare organizations.
“We offer different pricing models to meet diverse needs,” Moussa explains. “Monthly and quarterly subscriptions, as well as enterprise licenses, all at accessible prices.” The idea is to bring patients, healthcare professionals, and pharmaceutical companies into a shared ecosystem, rather than segmenting them into separate or exclusive markets.
At the core of the platform is the Intelligent Medication Checker: instant prescription validation, risk prevention, proactive alerts grounded in scientific evidence, and personalized solutions supported by secure EMR profiles. “Most foreign competitors operating in the MENA region focus exclusively on B2B solutions for institutions,” Moussa notes. “Very few address patients directly, or pharmaceutical companies, and none target all of them at once. That’s what makes us distinctive.”
Where algorithms meet clinical responsibility
Artificial intelligence powers error reduction, advances precision medicine, and delivers immediate insights. But which decisions does AI actually make, and which remain firmly in human hands? HealNOSTiC’s Medication Checker provides validations and alerts, yet the boundary between decision support and actual clinical decision-making remains a grey area across the health-tech sector.
In healthcare, legal and clinical accountability ultimately rests with professionals. An algorithm may flag a dangerous drug interaction, but it cannot prescribe or autonomously modify a therapy. This division of roles works when healthcare systems have solid infrastructure, trained staff, and clear regulatory frameworks. But what happens when these conditions are only partially met, or absent altogether? An alert ignored due to workload pressures, a notification misinterpreted because of insufficient training, or a technology deployed without adequate clinical context can turn a safety tool into a source of confusion.
Algorithmic transparency adds another layer of complexity. When AI recommends or discourages a drug combination, what data underpin that suggestion? How much of the reasoning process is traceable and verifiable by a clinician? Evidence-based medicine requires sources to be explicit and up to date, yet many machine-learning systems operate as black boxes, making it difficult to reconstruct the path leading to a recommendation. The issue is not mistrust of technology, but recognition that clinical reliability demands validation mechanisms that go beyond statistical accuracy.
Data security in fragmented regulatory environments
“We use high-security encryption for all incoming and outgoing data,” Moussa explains. “We operate in a highly regulated market: we are already HIPAA-compliant in the United States and are working toward European compliance.”
Regulatory compliance is a prerequisite in digital health, but standards vary widely across jurisdictions. HIPAA in the U.S., GDPR in Europe, and different frameworks in the Middle East each define health data protection differently. A global platform must navigate this fragmentation by adapting not only its technology, but also consent models, data-retention policies, and audit procedures.
There is also the question of data ownership. When a patient uses HealNOSTiC, information about their therapy feeds the system, anonymized, aggregated, and used to improve algorithms. This is a standard digital-platform model, but in healthcare it raises specific concerns. Health data carry clinical value, but also economic value. Who can access them? Who can monetize them? And how can technological innovation be balanced with patients’ rights to control their most sensitive information?
Alongside its focus on data protection, Moussa emphasizes social sustainability. HealNOSTiC aligns with the United Nations Sustainable Development Goals, particularly Goal 3 (Good Health and Well-being) and gender empowerment. “Around 75 to 80 percent of our team is made up of women,” she notes. In a tech sector still dominated by men, her experience suggests that performance and inclusion are not mutually exclusive.
Expanding across heterogeneous healthcare systems
Social commitment has not slowed HealNOSTiC’s expansion. The company operates primarily in Egypt, with partnerships across the MENA region and in Europe. “We are working with Swedish companies, have access to the Spanish market, and hope to enter Germany by the end of next year,” Moussa says, strategic choices targeting ecosystems with advanced healthcare and strong investment in digital health innovation.
Yet geographic expansion in healthcare is not simply a matter of translating interfaces or updating drug databases. Each healthcare system follows distinct clinical protocols, therapeutic guidelines, and prescribing practices. A medication commonly used in Egypt may be unavailable in Germany; an interaction deemed critical in the U.S. may be handled differently in Spain. The promise of AI-driven precision medicine must contend with the variability of real-world healthcare systems.
Cultural adoption also plays a role. In some contexts, clinicians are accustomed to decision-support systems and integrate them into daily practice. In others, technology may be perceived as intrusive or as a threat to professional autonomy. The effectiveness of a platform like HealNOSTiC depends not only on algorithm quality, but on how ready local healthcare systems are to adopt it, train staff, and adapt existing workflows.
Building credibility through institutional networks
Navigating such heterogeneous environments also requires institutional credibility, a particularly significant factor for tech startups operating in healthcare.
For a woman founder in the tech sector, this often entails developing specific strategies to counter gender bias. Moussa’s trajectory offers one example: collaborations with UN agencies such as UNESCO and ITU, followed by partnerships with UN Women and UNDP. In 2023, UNDP selected HealNOSTiC for the Mobile World Congress in Spain as one of the two leading Egyptian startups founded by women. That same year, Moussa was named among the top 100 women entrepreneurs in the MENA region by the International Finance Corporation (IFC) of the World Bank.
National support has also played a role. “I work out of one of ITIDA’s buildings – the Egyptian Ministry of Communications’ agency,” Moussa explains. “They’ve supported us since 2020 with office space and resources to develop the business.” Building institutional networks is a key element for overcoming barriers, whether related to gender, social background, or access to healthcare markets.
